Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

The treatment landscape of metastatic prostate cancer has evolved significantly over the
past two decades. Several landmark phase 3 trials led to new drug approvals and rapid …

Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplastic agents
that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Steroid hormone signaling induces vast gene expression programs which necessitate the
local formation of transcription factories at regulatory regions and large-scale alterations of …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

Background Targeted thorium-227 conjugates (TTCs) are an emerging class of targeted
alpha therapies (TATs). Their unique mode of action (MoA) is the induction of difficult-to …

Targeted α therapy (TAT) offers the potential for the targeted delivery of potent α-particle-
emitting radionuclides that emit high linear energy transfer radiation. This leads to a densely …

Abstract Radium‐223 (223Ra) is the first‐in‐class alpha‐emitter to mediate tumor
eradication, which is commonly thought to kill tumor cells by directly cleaving double‐strand …